Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Maraviroc

Maraviroc

Maraviroc is a CCR5 antagonist used to treat HIV infection.
It blocks the CCR5 co-receptor, preventing HIV from entering and infecting CD4+ T cells.
Maraviroc is indicated for use in treatment-experienced adult patients with CCR5-tropic HIV-1 infection.
It is typically used in combination with other antiretroviral medications to supress viral load and improve immune function.
Researchers can use PubCompare.ai to optimize Maraviroc studies by identifying the most reproducible and accurate protocols from the literature, preprints, and patents.
This AI-powered platform helps streamline research and enusre Maraviroc studies are a sucess.

Most cited protocols related to «Maraviroc»

1
Early Antiretroviral Therapy for Acute HIV
Cited 10 times
The RV254/SEARCH 010 study is an ongoing prospective, open-label study in Bangkok, Thailand (clinicaltrials.gov identification NCT00796146). The study was approved by the institutional review boards (IRBs) of Chulalongkorn University in Thailand and the Walter Reed Army Institute of Research in the United States. All subjects gave informed consent. Samples from subjects who had VCT for HIV at The Thai Red Cross Anonymous Clinic and at the Silom Community Clinic were screened in real-time by pooled NAT and sequential EIA according to published methods [13] (link). Thai subjects who fit the AHI laboratory criteria for Fiebig stages I to IV [14] (link) were enrolled (Figure 1) and had clinical and laboratory assessments at days 0, 2, 3, 5, 7, 10, weeks 2, 4, 8, 12, 16, 20, 24, and every 12 weeks thereafter up to 192 weeks. A checklist of ARS symptoms was employed by an HIV physician to assess all potential symptoms at the baseline and subsequent visits until all symptoms had resolved.
Laboratory assessments included CD4, HIV RNA, liver transaminases, creatinine, lipids and urinalysis. Plasma and peripheral blood mononuclear cells (PBMCs) were cryopreserved at all visits. Sampling of gut-associated lymphoid tissue (GALT) occurred at weeks 0 and 24 by sigmoidoscopy as an optional procedure (24 subjects at baseline and 13 subjects at week 24), and mucosal mononuclear cells (MMCs) were isolated from GALT.
Initiation of ART was voluntary and done as part of enrollment in an accompanying local protocol (clinicaltrials.gov identification NCT00796263), approved by the Chulalongkorn University IRB, and all subjects gave informed consent. Treatment was started on average 3 days (range 0–5 days) from enrollment. The regimen consisted of 5 antiretrovirals [tenofovir (TDF) 300 mg once daily, emtricitabine (FTC) 200 mg once daily, efavirenz (EFV) 600 mg once daily, raltegravir (RAL) 400 mg twice daily and maraviroc (MVC) 600 mg twice daily] for the first 24 weeks followed by simplification to 3 drugs with TDF, FTC and EFV. EFV was discontinued in subjects with intolerance or resistance, in which case dose adjustment of MVC to 300 mg twice daily was implemented. The first 10 subjects received the 5-drug regimen. Subsequently subjects were randomized 1∶1 (in a block of 30) to 5 drugs (MegaHAART) vs. 3 drugs (HAART with TDF, FTC, EFV) ART.
Ananworanich J., Schuetz A., Vandergeeten C., Sereti I., de Souza M., Rerknimitr R., Dewar R., Marovich M., van Griensven F., Sekaly R., Pinyakorn S., Phanuphak N., Trichavaroj R., Rutvisuttinunt W., Chomchey N., Paris R., Peel S., Valcour V., Maldarelli F., Chomont N., Michael N., Phanuphak P, & Kim J.H. (2012). Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection. PLoS ONE, 7(3), e33948.
Publication 2012
Antiretroviral Therapy, Highly Active Cells Creatinine efavirenz Lipids Liver Lymphoid Tissue Maraviroc Mucous Membrane PBMC Peripheral Blood Mononuclear Cells Pharmaceutical Preparations Physicians Plasma Proctosigmoidoscopy Raltegravir Tenofovir Thai Transaminases Treatment Protocols Urinalysis
2
Rhesus Macaque SIV Infection and ART Suppression
Cited 8 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Animals Animals, Laboratory Autopsy Cells Darunavir Diet Disease Progression Females Herpesvirus 1, Cercopithecine Human respiratory syncytial virus Infection Institutional Animal Care and Use Committees isolation Macaca mulatta Maraviroc Metals Plasma Primates Proteins Raltegravir Ritonavir RNA, Viral Superinfection Tenofovir Therapeutics Treatment Protocols Tuberculosis Viremia Virus
3
Proficiency Testing of Antiretroviral Drugs
Cited 8 times
Every six months the CPQA PT program offered prepared plasma samples containing pre-specified concentrations (unknown to CPLs) of up to 21 ARV analytes: abacavir (ABC), amprenavir (APV), atazanavir (ATV), darunavir (DRV), didanosine (DDI), efavirenz (EFV), emtricitabine (FTC), etravirine (ETR), indinavir (IDV), lamivudine (3TC), lopinavir (LPV), maraviroc (MVC), nelfinavir (NFV), nevirapine (NVP), raltegravir (RGV), ritonavir (RTV), saquinavir (SQV), stavudine (D4T), tenofovir (TFV), tipranavir (TPV), zidovudine (ZDV). In each round and for each ARV, 5 concentrations, spanning an expected therapeutic range of each ARV, as well as occasional concentrations below or above, were provided. Samples are prepared by an outside subcontractor and tested by the CPQA lab prior to distribution. PT samples were stored at −70 ± 15°C and then shipped on dry ice to participating laboratories with detailed instructions. Upon arrival, each laboratory confirmed sample integrity and indicated planned reporting of specific analytes. Results were reported either through an online Laboratory Data Management System (LDMS) or via a template which was then uploaded into the LDMS database. At the end of the submission period, a completeness evaluation was performed to confirm that all planned results were received; discrepancies were queried for resolution. To summarize the proficiency of individual labs, a pre-specified scoring algorithm was applied to the RCs (see next paragraph). The scoring algorithm reflects US Clinical Laboratory Improvement Act (CLIA) PT regulations[13 (link)]. After review and approval by the CPQA advisory board chair, a final report was sent to the participating laboratories (with laboratories de-identified) and key leadership (laboratories identified per network leader).
An individual RC is deemed Acceptable provided a concentration is present where expected, and the concentration is within 20% of the final target (FT)[14 (link)]. (If a concentration is reported as below the lower limit of quantification (BLQ), and the run lower limit was below 80%*FT, the concentration was labeled Unacceptable.) For a given prepared sample, if the number of labs reporting for that sample is large enough, the variability between CPLs is small enough (≤15%) and the percent deviation of the group mean (GM, determined after removal of outliers, if any)from the weighed-in value (WIV) is >5%, the FT is set to the GM. Otherwise, FT is set to the WIV. At the analyte level, a CPL’sperformance is deemed Satisfactory for the round provided at least 80% of RCs are Acceptable. If the CPL score is <80% for an analyte, the CPL submits a corrective action plan to reestablish accuracy; a root cause is requested. Finally, in accordance with CLIA rules, a lab is classified as successful for an analyte provided the round-specific score was Satisfactory in at least 2 of the last 3 rounds (including the current).
DiFrancesco R., Rosenkranz S.L., Taylor C.R., Pande P.G., Siminski S.M., Jenny R.W, & Morse G.D. (2013). Clinical Pharmacology Quality Assurance (CPQA) Program: Models for Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories. Therapeutic drug monitoring, 35(5), 631-642.
Publication 2013
abacavir amprenavir Atazanavir Clinical Laboratory Services Darunavir Dry Ice efavirenz etravirine Indinavir Lopinavir Maraviroc Nelfinavir Nevirapine Plant Roots Plasma Raltegravir Ritonavir Saquinavir Tenofovir Therapeutics tipranavir Zidovudine
4
Acute HIV Infection Study in Thailand
Cited 7 times
The current analysis encompassed data collected between April 2009 and July 2015 from participants enrolled in the RV254/SEARCH010 study (clinicaltrials.gov identification NCT00796146), which is an ongoing prospective study of AHI in Thailand. Briefly, clients of the Thai Red Cross Anonymous HIV testing Clinic in Bangkok were screened in real time for AHI by pooled nucleic acid testing (NAT) or sequential immunoassay as previously described [11 (link)]. Participants with a positive NAT and a non-reactive HIV IgG were invited to join the study.
Further testing was performed to categorise them into Fiebig stages as follows: Fiebig I (HIV-RNA+, p24 antigen-, HIV IgM−), Fiebig II (HIV-RNA+, p24 antigen+, HIV IgM−), Fiebig III (HIV IgM+, Western blot-) and Fiebig IV (HIV IgM+, Western blot indeterminate). The corresponding mean cumulative durations from onset of HIV viraemia according to Fiebig et al. are 5 (Fiebig I), 10.3 (Fiebig II), 13.5 (Fiebig III) and 19.1 (Fiebig IV) days [2 (link)]. For this study, we reported estimated infection duration from history of HIV exposure within the last 30 days. Flexible sigmoidoscopy and biopsy, and cerebrospinal fluid (CSF) collection were optional procedures. ART was also optional and offered as part of an accompanying protocol (clinicaltrials.gov identification NCT00796263). Treatment included standard doses of a three-drug regimen (tenofovir, lamivudine or emtricitabine, and efavirenz) with some participants receiving a five-drug regimen with the addition of raltegravir and maraviroc during the first 24 weeks. The Thai Chulalongkorn University and relevant US and Canadian institutional review boards approved these studies. All participants provided informed consent.
Laboratory methods were based on assays previously described by our group [12 (link),13 (link)]. CD4 cell count was measured by dual-platform flow cytometry (Becton-Dickinson, USA). HIV-RNA in plasma and CSF was performed using the COBAS AMPLICOR HIV-1 Monitor Test v1.5 or Cobas Taqman v2.0 (Roche Molecular Systems, USA). The Siemens Quantiplex HIV-1 3.0 assay was used to measure HIV-RNA (copy/mg of gut tissue). Total HIV-DNA in peripheral blood mononuclear cells (PBMCs) and sigmoid colon were quantified using a modified nested PCR assay for CRF01_AE and B [14 (link)]. Immunophenotyping was performed on PBMCs for activated CD4 (CD4+HLA-DR+CD38+) and CD8 (CD8+HLA-DR+CD38+) T cells as previously described [5 (link)]. Plasma soluble CD14 (sCD14) and interleukin 6 (IL-6) were measured by ELISA (R&D Systems, Minneapolis, Minnesota, USA). HIV subtyping was performed using the multi-region hybridisation real-time PCR assay for subtypes B, C and CRF01_AE [15 (link)].
Ananworanich J., Sacdalan C.P., Pinyakorn S., Chomont N., Souza M., Luekasemsuk T., Schuetz A., Krebs S.J., Dewar R., Jagodzinski L., Ubolyam S., Trichavaroj R., Tovanabutra S., Spudich S., Valcour V., Sereti I., Michael N., Robb M., Phanuphak P., Kim J.H, & Phanuphak N. (2016). Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal of Virus Eradication, 2(1), 43-48.
Publication 2016
Antigens Biological Assay Biopsy CD4+ Cell Counts Cerebrospinal Fluid Crossbreeding efavirenz Emtricitabine Enzyme-Linked Immunosorbent Assay Ethics Committees, Research Flow Cytometry HIV-1 HIV Infections HLA-DR Antigens Immunoassay Interleukin-6 Lamivudine Maraviroc Nested Polymerase Chain Reaction PBMC Peripheral Blood Mononuclear Cells Pharmaceutical Preparations Plasma Proctosigmoidoscopy Raltegravir Real-Time Polymerase Chain Reaction RNA, immune Sigmoid Colon Soluble CD14 Protein T-Lymphocyte Tenofovir Testing, HIV Thai Tissues Treatment Protocols Viremia Western Blotting
5
Evaluating HIV-1 Vaginal Infection in Mice
Cited 6 times
Female RAG-hu mice were administered with either raltegravir or maraviroc by oral gavage (6 mice each). Clinical formulations of these drugs in tablet form (Maraviroc (Selzentry) 150 mg, Pfizer Labs; Raltergravir (Isentress) 400 mg, Merck & Co) were freshly dissolved in distilled water each day prior to oral gavage. Mouse equivalent drug doses were calculated by using an interspecies allometric scaling factor of 12.3 to arrive at 164 mg/kg and 62 mg/kg doses for raltegravir and maraviroc respectively [34] (link), [35] (link). Mice (six per group) received either raltegravir (3.28 mg per 20 gram mouse) or maraviroc (1.23 mg per 20 gram mouse) by oral gavage daily. Mice were challenged with HIV-1 vaginally on the 4th day of treatment and the drug treatment continued for 3 more days. For vaginal viral challenges, cell-free HIV-1 strain BaL-1 (R5 tropic virus) contained in the original media used to produce the virus (RPMI 1640 medium supplemented with 10% fetal bovine serum) was used. Vaginal infections were performed in a volume of 20 µl (3000 TCID of BaL-1 virus). Sterile P200 tips that had been previously heated over a flame to smooth any abrasive surfaces were used to deliver the virus [30] (link). Anesthetized mice were held in an inverted position for four minutes post-inoculation to allow virus to adsorb and to prevent immediate discharge of virus. Control non-treated mice (n = 7) were also challenged similarly by the vaginal route. Mice were observed daily and blood samples drawn weekly to assess plasma viremia.
Neff C.P., Ndolo T., Tandon A., Habu Y, & Akkina R. (2010). Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model. PLoS ONE, 5(12), e15257.
Publication 2010
ARID1A protein, human BLOOD Cultured Cells Factor XII Fetal Bovine Serum HIV-1 Infection Isentress Maraviroc Mice, House Pharmaceutical Preparations Plasma Raltegravir Selzentry Sterility, Reproductive Tablet Tube Feeding Vaccination Vagina Viremia Virus Virus Release Woman

Most recents protocols related to «Maraviroc»

1
Extracellular Vesicle Separation in SIV-Infected Primates
All samples were from archives of studies approved by the Johns Hopkins University Institutional Animal Care and Use Committee and conducted in accordance with the Weatherall Report, the Guide for the Care and Use of Laboratory Animals, and the USDA Animal Welfare Act. For initial studies and verification of extracellular vesicle separations, plasma samples were obtained from pigtailed macaques that were not infected (n = 2) or dual-inoculated with SIV swarm B670 and clone SIV/17E-Fr and untreated (n = 3) or treated then treatment interruption (“rebound,” n = 3); (Supplemental Table 1). Longitudinal verification samples were from two cohorts of six pigtailed macaques dual-inoculated as above [28 (link),29 (link)] and treated with ART (consisting of once daily subcutaneous 2.5 mg/kg dolutegravir, 20 mg/kg tenofovir, and 30 mg/kg emtricitabine) boosted or not with maraviroc, and a cohort of six rhesus macaques infected with SIVmac251 [30 ,31 (link)] and treated with ART (Supplemental Table 2). For pigtails, ART started at 12 days postinoculation (dpi), and for rhesus, at 14 dpi. Time points were preinfection (two draws), acute infection (7, 14 dpi), latent infection (ART-suppressed) (86, 154 dpi), rebound [12 days ART treatment interruption (postrelease (dpr)], and necropsy. Additional pigtailed samples (uninfected, n = 3 and acute infected 7 dpi, n = 3) were used for density separations (Supplemental Table 3).
Huang Y., Liao Z., Dang P., Queen S., Abreu C.M., Gololobova O., Zheng L, & Witwer K.W. (2023). Longitudinal characterization of circulating extracellular vesicles and small RNA during simian immunodeficiency virus infection and antiretroviral therapy. AIDS (London, England), 37(5), 733-744.
Publication 2023
Animals, Laboratory Autopsy Clone Cells dolutegravir Emtricitabine Extracellular Vesicles Infection Institutional Animal Care and Use Committees Latent Infection Macaca mulatta Macaca nemestrina Maraviroc Plasma Tenofovir
2
HuMoSC Chemotaxis Assay with Inhibitors
HuMoSC chemotaxis was assessed using Boyden chambers with 10 μm pore polycarbonate filters. The lower chamber was filled with undiluted supernatants of control TAB or GCA-TAB cultivated for five days in MATRIGEL. A total of 30.103 HuMoSC/well in 50 µL of 10% FBS RPMI medium were loaded in the upper chamber. In selected chambers, an antagonist of CCR2 (Calbiochem, used at 100 nM) or CCR5 (maraviroc, R&D Systems, used at 1 µM) was added. After 4.5-hour incubation, the polycarbonate membrane was stained with hematoxylin and eosin and washed before counting number of cells/field.
Samson M., Genet C., Corbera-Bellalta M., Greigert H., Espígol-Frigolé G., Gérard C., Cladière C., Alba-Rovira R., Ciudad M., Gabrielle P.H., Creuzot-Garcher C., Tarris G., Martin L., Saas P., Audia S., Bonnotte B, & Cid M.C. (2023). Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis. Frontiers in Immunology, 14, 1137794.
Publication 2023
A 103 CCR5 protein, human Chemotaxis Eosin Maraviroc matrigel polycarbonate Tissue, Membrane
3
PASC Patients Treated with Maraviroc and Pravastatin
The records and immunological lab reports from 18 adult PASC patients treated with maraviroc 300 mg per oral twice daily and pravastatin 10 mg per oral daily from our virtual medical clinic were collected and analyzed.
The 18 participants selected for this case series were from a pool of patients who reported symptom improvement while on maraviroc and pravastatin and who fit the inclusion and exclusion criteria we set below.
Patterson B.K., Yogendra R., Guevara-Coto J., Mora-Rodriguez R.A., Osgood E., Bream J., Parikh P., Kreimer M., Jeffers D., Rutland C., Kaplan G, & Zgoda M. (2023). Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Frontiers in Medicine, 10, 1122529.
Publication 2023
Adult Maraviroc Pancreatic Stellate Cells Patients Pravastatin
4
Discontinuation of Maraviroc and Pravastatin
When patients reported that their post-COVID symptoms improved by 80% of greater, we initiated discontinuation of both maraviroc and pravastatin. Bi-monthly follow-ups were conducted for 12 weeks post-treatment to monitor if symptoms reappeared or worsened.
Patterson B.K., Yogendra R., Guevara-Coto J., Mora-Rodriguez R.A., Osgood E., Bream J., Parikh P., Kreimer M., Jeffers D., Rutland C., Kaplan G, & Zgoda M. (2023). Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Frontiers in Medicine, 10, 1122529.
Publication 2023
Maraviroc Patients Pravastatin
5
Measuring Post-Acute Sequelae of SARS-CoV-2 Infection
A challenge in studying and defining PASC is the heterogenous clinical presentation and multisystem involvement. Thus, we categorized the main participant symptoms into 5 groups: neurological/autonomic function, cardiac, respiratory, overall functionality, and fatigue. Since there are no validated scales for PASC, we used five validated scales for other organ systems [New York Heart Association (NYHA), Modified Rankin Scale for Neurologic Disability, Fatigue Severity Scale (FSS), COMPASS-31 and Medical Research Council (MRC) Dyspnea Scale, respectively] to measure subjective participant responses to treatment (Tables 1–5). Participants were administered validated self-questionnaires about their PASC symptoms before and after treatment with maraviroc and pravastatin treatment. The length of duration of treatment varied based on repeat immune markers and participant-reported symptom improvement. Since many of these participants were on other medications and anti-inflammatories prior to starting maraviroc and pravastatin, the biomarkers and subjective data presented are from the onset of this combination. Phone interviews were conducted with each participant before and after subjective responses to the medications.
The New York Heart Association (NYHA) functional classification was used to classify severity of PASC associated cardiac symptoms.
The Composite Autonomic Symptom Scale 31 (COMPASS 31), a self-rating questionnaire consisting of 31 items and evaluating orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor function, was used to measure autonomic dysfunction and the subsequent therapeutic effects of maraviroc and pravastatin. A sub raw score for each of the six domains was calculated and converted into a weighted sub-score. The sum of this weighted sub-score gave a total score which ranged from 0 to 100, with 0 meaning no autonomic symptoms and 100 reflecting the most severe autonomic symptoms.
Medical Research Council (MRC) Dyspnea scale is a validated method comprised of five statements that aims to measure perceived feeling of breathlessness.
The Modified Rankin scale for neurologic disability is a validated scale to measure degree of disability after suffering a stroke or neurological insult.
The Fatigue Severity Scale (FSS) questionnaire is a nine-statement validated scale that rates the severity of fatigue symptoms. Participants were asked how accurately each statement reflected their condition before and after treatment with maraviroc and pravastatin and the extent to which they agreed or disagreed based on a scale of 1 (strongly disagree) to 7 (strongly agree).
Patterson B.K., Yogendra R., Guevara-Coto J., Mora-Rodriguez R.A., Osgood E., Bream J., Parikh P., Kreimer M., Jeffers D., Rutland C., Kaplan G, & Zgoda M. (2023). Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Frontiers in Medicine, 10, 1122529.
Publication 2023
Aftercare Anti-Inflammatory Agents Biological Markers Cerebrovascular Accident Disabled Persons Dysautonomia Dyspnea Fatigue Genetic Heterogeneity Heart Maraviroc Nervous System, Autonomic Nervous System Physiological Phenomena Pancreatic Stellate Cells Pharmaceutical Preparations Pravastatin Respiratory Rate Systems, Nervous Therapeutic Effect Urinary Bladder

Top products related to «Maraviroc»

1
Maraviroc by Merck Group
Sourced in United States
Maraviroc is a type of antiretroviral medication used in the treatment of HIV infection. It functions as an entry inhibitor, blocking the CCR5 co-receptor on the surface of host cells, thereby preventing the virus from entering and infecting those cells.
2
Maraviroc by Selleck Chemicals
Sourced in United States
Maraviroc is a laboratory-grade chemical used in research applications. It functions as a CCR5 antagonist, inhibiting the CCR5 receptor. The core purpose of Maraviroc is to serve as a research tool for studying receptor-ligand interactions and their potential applications.
3
Maraviroc by Cayman Chemical
Sourced in United States
Maraviroc is a laboratory reagent used for research purposes. It functions as a CCR5 antagonist, which is a type of chemical compound that binds to and blocks the CCR5 receptor on the surface of cells.
4
Maraviroc by R&D Systems
Sourced in United Kingdom
Maraviroc is a lab reagent that functions as a CCR5 antagonist. It is used in research studies to investigate the role of the CCR5 chemokine receptor in various biological processes.
5
Maraviroc by Pfizer
Sourced in United Kingdom
Maraviroc is a laboratory product developed by Pfizer. It is a small molecule that functions as a CCR5 antagonist, which blocks the interaction between the CCR5 co-receptor and the HIV-1 virus, thereby inhibiting viral entry into host cells.
6
Maraviroc by Bio-Techne
Sourced in United Kingdom, United States
Maraviroc is a laboratory reagent used in scientific research. It is a small-molecule inhibitor that binds to the CCR5 receptor, which is a co-receptor for the human immunodeficiency virus (HIV). Maraviroc can be used in in vitro and in vivo studies to investigate the role of the CCR5 receptor in various biological processes.
7
Maraviroc by MedChemExpress
Sourced in United States, Sweden
Maraviroc is a laboratory reagent used for research purposes. It functions as a CCR5 antagonist, which means it binds to and blocks the CCR5 receptor on cells. The core function of Maraviroc is to serve as a research tool for studying CCR5-related cellular processes and pathways.
8
Matrigel by BD
Sourced in United States, United Kingdom, Germany, China, Canada, Japan, Italy, France, Belgium, Australia, Uruguay, Switzerland, Israel, India, Spain, Denmark, Morocco, Austria, Brazil, Ireland, Netherlands, Montenegro, Poland
Matrigel is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. It is widely used as a substrate for the in vitro cultivation of cells, particularly those that require a more physiologically relevant microenvironment for growth and differentiation.
9
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
10
Deae dextran by Merck Group
Sourced in United States, Germany, Japan, France
DEAE-dextran is a positively charged polymer derived from the carbohydrate dextran. It is commonly used in various laboratory applications as a reagent or tool for biomolecular research and analysis.

More about "Maraviroc"

Maraviroc is a potent and selective CCR5 antagonist, used as an antiretroviral medication to treat HIV (human immunodeficiency virus) infection.
It works by blocking the CCR5 co-receptor, preventing the virus from entering and infecting CD4+ T cells, a critical immune cell type.
Maraviroc is typically prescribed in combination with other antiretroviral drugs to suppress viral load and improve immune function in treatment-experienced adult patients with CCR5-tropic HIV-1 infection.
Researchers can utilize PubCompare.ai, an AI-powered platform, to optimize their Maraviroc studies.
This tool helps identify the most reproducible and accurate protocols from the scientific literature, preprints, and patents, streamlining the research process and ensuring the success of Maraviroc-related studies.
In addition to Maraviroc, researchers may also work with other compounds like Matrigel, a complex extracellular matrix mixture derived from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, and DMSO (dimethyl sulfoxide), a widely used solvent.
DEAE-dextran, a cationic polymer, can also be employed in various cell culture and transfection protocols.
By leveraging the insights and capabilities of PubCompare.ai, scientists can enhance their Maraviroc research, locate the optimal experimental protocols, and ultimately, contribute to the advancement of HIV treatment and management.